MA37893A1 - Dérivés de la pyridine inhibiteur de la cathepsin utile pour le traitement ou la prophylaxie du diabete, atherosclerose, anevrisme de l'aorte abdominale, maladie arterielle peripherique ou diabete nephrotique. - Google Patents

Dérivés de la pyridine inhibiteur de la cathepsin utile pour le traitement ou la prophylaxie du diabete, atherosclerose, anevrisme de l'aorte abdominale, maladie arterielle peripherique ou diabete nephrotique.

Info

Publication number
MA37893A1
MA37893A1 MA37893A MA37893A MA37893A1 MA 37893 A1 MA37893 A1 MA 37893A1 MA 37893 A MA37893 A MA 37893A MA 37893 A MA37893 A MA 37893A MA 37893 A1 MA37893 A1 MA 37893A1
Authority
MA
Morocco
Prior art keywords
diabetes
nephrotic
prophylaxis
atherosclerosis
pyridine
Prior art date
Application number
MA37893A
Other languages
English (en)
French (fr)
Inventor
Bernd Kuhn
Lilli Anselm
David Banner
Wolfgang Haap
Thomas Luebbers
Jens-Uwe Peters
Beat Spinnler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46851300&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37893(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA37893A1 publication Critical patent/MA37893A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
MA37893A 2012-08-21 2013-08-19 Dérivés de la pyridine inhibiteur de la cathepsin utile pour le traitement ou la prophylaxie du diabete, atherosclerose, anevrisme de l'aorte abdominale, maladie arterielle peripherique ou diabete nephrotique. MA37893A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12181247 2012-08-21
PCT/EP2013/067218 WO2014029722A1 (en) 2012-08-21 2013-08-19 Novel pyridine derivatives

Publications (1)

Publication Number Publication Date
MA37893A1 true MA37893A1 (fr) 2017-08-31

Family

ID=46851300

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37893A MA37893A1 (fr) 2012-08-21 2013-08-19 Dérivés de la pyridine inhibiteur de la cathepsin utile pour le traitement ou la prophylaxie du diabete, atherosclerose, anevrisme de l'aorte abdominale, maladie arterielle peripherique ou diabete nephrotique.

Country Status (24)

Country Link
US (1) US9409882B2 (en:Method)
EP (1) EP2888244A1 (en:Method)
JP (1) JP2015530997A (en:Method)
KR (1) KR20150044947A (en:Method)
CN (1) CN104583198A (en:Method)
AR (1) AR092172A1 (en:Method)
AU (1) AU2013305102A1 (en:Method)
BR (1) BR112015003217A2 (en:Method)
CA (1) CA2879796A1 (en:Method)
CL (1) CL2015000354A1 (en:Method)
CO (1) CO7200259A2 (en:Method)
CR (1) CR20150073A (en:Method)
EA (1) EA025166B1 (en:Method)
HK (1) HK1206716A1 (en:Method)
IL (1) IL237128A0 (en:Method)
IN (1) IN2015DN00962A (en:Method)
MA (1) MA37893A1 (en:Method)
MX (1) MX2015002026A (en:Method)
PE (1) PE20150995A1 (en:Method)
PH (1) PH12015500262A1 (en:Method)
SG (1) SG11201500900YA (en:Method)
TW (1) TW201412728A (en:Method)
WO (1) WO2014029722A1 (en:Method)
ZA (1) ZA201500625B (en:Method)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY196560A (en) * 2016-02-26 2023-04-19 Hoffmann La Roche Novel Pyrrolidine Derivatives
PT3575284T (pt) 2017-01-24 2021-10-01 Astellas Pharma Inc Composto de prolinamida substituído por fenildifluorometilo

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9903610D0 (sv) 1999-10-06 1999-10-06 Astra Ab Novel compounds II
RU2007129779A (ru) 2005-01-06 2009-02-20 Астразенека Аб (Se) Новые соединения пиридина
BRPI0706725A2 (pt) 2006-01-24 2011-04-05 Actelion Pharmaceuticals Ltda Composto de sais do mesmo , composição farmacêutica , e , uso de um composto
CN104447716A (zh) * 2007-05-09 2015-03-25 沃泰克斯药物股份有限公司 Cftr调节剂
KR20100072098A (ko) 2007-11-30 2010-06-29 에프. 호프만-라 로슈 아게 피리딘 화합물
ES2389042T3 (es) 2008-03-06 2012-10-22 Actelion Pharmaceuticals Ltd. Compuestos de piridina
KR101320790B1 (ko) * 2009-04-20 2013-10-22 에프. 호프만-라 로슈 아게 카텝신 억제제로서의 프롤린 유도체
US8394834B2 (en) * 2009-08-25 2013-03-12 Hoffman-La Roche Inc. Pyrrolidines as NK3 receptor antagonists
EP2760833A1 (en) 2011-09-30 2014-08-06 Endo Pharmaceuticals Inc. Pyridine derivatives

Also Published As

Publication number Publication date
CR20150073A (es) 2015-03-13
IL237128A0 (en) 2015-03-31
AU2013305102A1 (en) 2015-02-12
HK1206716A1 (en) 2016-01-15
WO2014029722A1 (en) 2014-02-27
US9409882B2 (en) 2016-08-09
IN2015DN00962A (en:Method) 2015-06-12
KR20150044947A (ko) 2015-04-27
CO7200259A2 (es) 2015-02-27
EA025166B1 (ru) 2016-11-30
CN104583198A (zh) 2015-04-29
EA201590363A1 (ru) 2015-06-30
ZA201500625B (en) 2016-08-31
US20150307472A1 (en) 2015-10-29
PE20150995A1 (es) 2015-06-29
BR112015003217A2 (pt) 2017-07-04
PH12015500262A1 (en) 2015-03-30
SG11201500900YA (en) 2015-03-30
CL2015000354A1 (es) 2015-10-23
AR092172A1 (es) 2015-03-25
TW201412728A (zh) 2014-04-01
MX2015002026A (es) 2015-06-05
CA2879796A1 (en) 2014-02-27
EP2888244A1 (en) 2015-07-01
JP2015530997A (ja) 2015-10-29

Similar Documents

Publication Publication Date Title
MA38403A1 (fr) Nouveaux dérivés de pyrazole modulateurs specifiques de cb2
MA35364B1 (fr) Dérivés hétérocycliques bicycliques pour le traitement d'une hypertension artérielle pulmonaire
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA32171B1 (fr) Compose heterocyclique
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
MA41562B1 (fr) Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires
MA35750B1 (fr) Dérivés de nucléoside substitué 2',4'-difluoro-2'-méthyle en tant qu'inhibiteurs de la réplication de l'arn du vhc (virus de l'hépatite c)
MA33224B1 (fr) Derives de proline comme inhibiteurs de la cathepsine
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MA45782B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA32468B1 (fr) Derives de thiophene ou de thiazole et leur utilisation comme inhibiteurs de pi3k
MA35085B1 (fr) Procede de traitement d'une nephropathie induite par les produits de contraste
MA35128B1 (fr) Nouveaux dérivés d'imidazole utiles pour le traitement de l'arthrite
MA34837B1 (fr) Composés indoliques ou analogues de ceux-ci utiles dans le traitement de la dégénérescence maculaire liée à l'âge (dmla)
MA38661A1 (fr) Composés hétéro-aromatiques et leur utilisation en tant que ligands d1 de la dopamine
MA33636B1 (fr) Dérivés aminopropioniques substitués comme inhibiteurs de néprilysine
GT201400031A (es) Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2
MA31710B1 (fr) (carboxylalkylenephenyl)phényloxamides, procédés pour la production de ceux-ci et utilisation de ceux-ci en tant que medicament
MA41238B1 (fr) Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit
MA38460B1 (fr) Dérivés de la purine en tant qu'agonistes du récepteur cb2
MA32108B1 (fr) Derives d'indazole
MA39165A1 (fr) Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires
MA38679A1 (fr) Modulateurs du récepteur de cxcr7
MA38410A1 (fr) Composés d'azétidinyloxyphénylpyrrolidine
MA39315A1 (fr) Dérivés de pyridazine à utiliser dans la prévention ou le traitement d'un trouble ataxique